References
Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden. Frisk P, Aggefors K, Cars T, Feltelius N, Loov SA, Wettermark B, Weiland O.Eur J Clin Pharmacol. 2018 Jul;74(7):971-978. doi: 10.1007/s00228-018-2456-y. Epub 2018 Apr 9.PMID: 29632961
Kamal H, Westman G, Falconer K, et al. Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes. Hepatology. 2020 Oct;72(4):1177-1190. doi: 10.1002/hep.31214. Epub 2020 Sep 24.
Lindgren P, Löfvendahl S, Brådvik G, Weiland O. Reduced work absenteeism in patients with hepatitis C treated with second-generation direct-acting antivirals. J Viral Hepatit. 2021 Jan;28(1):142-146. doi: 10.1111/jvh.13398. Epub 2020 Sep 22.
Westin J, Aleman S, Castedal M, et al. Management of hepatitis B virus infection, updated Swedish guidelines. Infect Dis (Lond). 2020 Jan;52(1):1-22. doi: 10.1080/23744235.2019.1675903.
Simon TG, Duberg AS, Aleman S, et al. Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. N Engl J Med. 2020 Mar 12;382(11):1018-1028. doi: 10.1056/NEJMoa1912035.
Kåberg M, Larsson SB, Jerkeman A, et al. High risk of non-alcoholic liver disease mortality in patients with chronic hepatitis C with illicit substance use disorder. Scand J Gastroenterol. 2020 May;55(5):574-580.
Mejer N, Fahnøe U, Galli A, et al. Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity. Antimicrob Agents Chemother. 2020 Nov 17;64(12): e01417-20.
Kamal H, Weiland O, Aleman S. The majority of patients with chronic HDV infection need better treatment options. Hepatology. 2020 Aug 7. doi: 10.1002/hep.31508. Online ahead of print.
Westin J, Aleman S, Castedal M, et al. Management of hepatitis B virus infection Swedish guidelines. Infect Dis (Lond). 2020;52(1):1-22.
Kåberg M, Weiland O. Hepatitis C elimination - Macro-elimination. Liver Int. 2020 Feb;40 Suppl. 1:61-66. doi: 10.1111/liv.14 352.
Kåberg M, Karlsson N, Discacciati A, et al. Significant decrease in injection risk behaviours among participants in a needle exchange programme. Infect Dis (Lond). 2020 May;52(5):336-346.
Aleman S, Söderholm J, Büsch K, et al. Frequent loss to follow-up after diagnosis of hepatitis C virus infection: A barrier towards the elimination of hepatitis C virus. Liver Int. 2020.
Kamal H, Fornes R, Simin J, et al. Risk of Hepatocellular Carcinoma in Hepatitis B and D Virus Co-Infected Patients: A Systematic Review and Meta-analysis of Longitudinal Studies. J Viral Hepat. 2021 Jul 22. doi: 10.1111/jvh.13577. Epub ahead of print. PMID: 34291520.
Blach S, Blomé M, Duberg AS, et al. Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID-19. Liver Int. 2021 May 29. doi: 10.1111/liv.14978. Epub ahead of print. PMID: 34051065.
Kamal H, Westman G, Falconer K, et al. A long-term study of a nationwide cohort of hepatitis B and D co-infected patients at secondary care centers: the impact of hepatitis D viremia on liver-related outcomes. Hepatology. 2020 Oct;72(4):1177-1190. doi: 10.1002/hep.31214. PMID: 32145073.
Lindgren P, Löfvendahl S, Brådvik G, Weiland O. Reduced work absenteeism in patients with hepatitis C treated with second-generation direct-acting antivirals. J Viral Hepat. 2021;28:142–146.
Lybeck C, Bruce D, Montgomery S, Aleman S, Duberg AS. Risk of hepatocellular carcinoma after DAA treatment and association with pretreatment liver stiffness in a national hepatitis C cohort. In manuscript.
Duberg AS, Lybeck C, Fält A, Montgomery S, Aleman S. Chronic hepatitis B virus infection and the risk of hepatocellular carcinoma by age and country of origin in people living in Sweden: A national register study. Hepatol Commun. 2022 May 3. doi: 10.1002/hep4.1974. Epub ahead of print. PMID: 35503810.
Howe AYM, Rodrigo C, Cunningham EB, et al. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. JHEP Rep. 2022 Feb.
Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022 Feb 15:S2468-1253(21)00472-6. doi: 10.1016/S2468-1253(21)00472-6.
Colombe S, Axelsson M, Aleman S, Duberg AS, et al. Monitoring the progress towards the elimination of hepatitis B and C in Sweden: estimation of core indicators for 2015 and 2018. BMC Infect Dis. 2022 Nov 25;22(1):885. doi: 10.1186/s12879-022-07886-2. PMID: 36434533; PMCID: PMC9700967.
Kamal H, Ingre M, Stål P, et al. Age-specific and sex-specific risks for HCC in African-born persons with chronic hepatitis B without cirrhosis. Hepatol Commun. 2023;7(12).
Polaris Observatory Collaborators. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories. J Hepatol. 2023.
Kamal H, Lindahl K, Ingre M, et al. The cascade of care for patients with chronic hepatitis delta in Southern Stockholm, Sweden for the past 30 years. Liver Int. 2023.
Westin J, Ydreborg M, Kampmann C, et al. Dismal prognosis for cirrhotic patients with hepatitis C after initial failure of direct-acting antivirals, but salvage therapy may be life-saving. Infect Dis (Lond). 2023;55(11):786-793.
Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol. 2023;8(10):879-907.
Wedemeyer H, Aleman S, Brunetto MR, et al. A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D. N Engl J Med. 2023;389(1):22-32.
Hollnberger J, Liu Y, Xu S, et al. No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks of treatment in phase II and III clinical trials for chronic hepatitis delta. J Hepatol. 2023;79(3):657-665.
Razavi HA, Buti M, Terrault NA, et al. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries. J Hepatol. 2023.
Ydreborg M, Lundström E, Kolleby R, et al. Linkage to hepatitis C treatment in two opioid substitution treatment units in Gothenburg, Sweden: a retrospective cohort study. Subst Abuse Treat Prev Policy. 2023;18(1):17.
Clinical findings in a multi-ethnic adult hepatitis B virus patient population in Denmark with emphasis on genotypic characteristics. Brinck-Jensen NS, Erichsen P, Tarp B, Lindberg J, Kristensen LH, Erlandsen M, Petersen E, Leutscher PD; InfCare Hepatitis DK group.Scand J Gastroenterol. 2015 Aug;50(8):1032-8. doi: 10.3109/00365521.2014.974202. Epub 2015 Apr 10.PMID: 25861877
Sweden, the first country to achieve the Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO) 90-90-90 continuum of HIV care targets. Gisslén M, Svedhem V, Lindborg L, Flamholc L, Norrgren H, Wendahl S, Axelsson M, Sönnerborg A.HIV Med. 2017 Apr;18(4):305-307. doi: 10.1111/hiv.12431. Epub 2016 Aug 18.PMID: 27535540
Andersson E, Nordquist A, Esbjörnsson J, et al. Increase in transmitted drug resistance in migrants from sub-Saharan Africa diagnosed with HIV-1 in Sweden. AIDS. 2018 Apr 24;32(7):877-884. doi: 10.1097/QAD.0000000000001763.
Andersson E, Nakagawa F, Van Sighem A, et al. Challenges in modelling the proportion of undiagnosed HIV infections in Sweden. Eurosurveillance. In press. Accepted November 28, 2018.
Ilson A, Bannert N, Sönnerborg A, et al. Temporal trends of transmitted HIV drug resistance in a multinational seroconversion. AIDS. 2018 Jan 14;32(2):161-169. PMID: 29112061.
Sörstedt E, Carlander C, Flamholc L, et al. Effect of dolutegravir in combination with nucleoside reverse transcriptase inhibitors on people living with HIV who have pre-existing mutations. Int J Antimicrob Agents. 2018 Jan 22. doi: 10.1016/j.ijantimicag.2018.01.009.
Santacatterina M, Bellocco R, Sönnerborg A, et al. Optimal probability weights for estimating causal effects of time-varying treatments. Stat Med. 2018 Dec 27. doi: 10.1002/sim.8080.
Schultze A, Torti C, Cozzi-Lepri A, et al. The effect of primary drug resistance on CD4 cell decline and the viral load set-point. AIDS. 2018 Oct 15. doi: 10.1097/QAD.0000000000002046.
Rogers LC, Obasa AE, Jacobs GB, et al. Structural implications of genotypic variations in HIV-1 integrase from diverse subtypes. Front Microbiol. 2018 Aug 2;9:1754. doi: 10.3389/fmicb.2018.01754.
Carlander C, Wagner P, Beirs AV, et al. Suppressive antiretroviral therapy associates with effective treatment of high-grade cervical intraepithelial neoplasia. AIDS. 2018 Jul 17;32(11):1475-1484.
Buggert M, Nguyen S, McLane L, et al. Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells. PLoS Pathog. 2018 Apr 13;14(4):e1006973.
Noyan K, Nguyen S, Betts MR, et al. HIV-1 Elite Controllers maintain low co-expression of inhibitory receptors on CD4+ T cells. Front Immunol. 2018 Jan 22;9:19. doi: 10.3389/fimmu.2018.00019.
Neogi U, Singh K, Aralaguppe SG, et al. Ex vivo antiretroviral potency of newer integrase strand transfer inhibitors. AIDS. 2018 Feb 20;32(4):469-476. doi: 10.1097/QAD.0000000000001726.
Zhang W, Ambikan A, Sperk M, et al. Transcriptomics and targeted proteomics analysis to gain insights into HIV-1 infected Elite Controllers. EBioMedicine. 2018 Jan; 27:40-50.
Vesterbacka J, Rivera J, Noyan K, et al. Richer gut microbiota with distinct metabolic profile in HIV-infected Elite Controllers. Sci Rep. 2017 Jul 24;7(1):6269.
Burbelo PD, Price RW, Hagberg L, et al. Anti-HIV antibodies in cerebrospinal fluid. J Infect Dis. 2018 Mar;217(7):1024-1032.
Calcagno A, Pinetti C, Ariaudo A, et al. Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients. Br J Clin Pharmacol. 2018;84(6):1380-1383.
De Coninck Z, Hussain-Alkhateeb L, Ekström AM, et al. Non-AIDS mortality is higher among successfully treated HIV patients. AIDS Pat Care STI. 2018 Aug;32(8):297-305.
Ulfhammer G, Edén A, Mellgren Å, et al. Persistent central nervous system immune activation. AIDS. 2018;32:2171-2178.
Premeaux TA, D’Antoni ML, Abdel-Mohsen M, et al. Elevated Cerebrospinal Fluid Galectin-9 is Associated with CNS Immune Activation. J Neurovirol. 2018 Nov 26.
Joseph SB, Kincer LP, Bowman NM, et al. HIV-1 RNA detected in CNS after years of ART suppression. Clin Infect Dis. 2018 Dec 18.
Gisslén M, Heslegrave A, Veleva E, et al. CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1. Neurol Neuroimmunol Neuroinflamm. 2018 Nov 7;6(1):e512.
Dickinson L, Gurjar R, Stöhr W, et al. Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults. J Antimicrob Chemother. 2019.
Lathouwers E, Wong EY, Brown K, et al. Week 48 Resistance Analyses of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1. AIDS Res Hum Retroviruses. 2020.
Eron JJ, Orkin C, Cunningham D, et al. Week 96 efficacy and safety results of switching to the once-daily regimen D/C/F/TAF in treatment-experienced, virologically-suppressed adults. Antiviral Res. 2019.
Storm-Larsen C, Stiksrud B, Eriksen C, et al. Microbial translocation revisited: targeting the endotoxic potential of gut microbes in HIV-infected individuals. AIDS. 2019.
Laut K, Kirk O, Rockstroh J, et al. The EuroSIDA study: 25 years of scientific achievements. HIV Med. 2019.
Neesgaard B, Pelchen-Matthews A, Ryom L, et al. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals. AIDS. 2019.
Giardina F, Romero-Severson EO, Axelsson M, et al. Estimation of incidence and undiagnosed population size using multiple biomarkers. HIV Med. 2019.
Amele S, Peters L, Sluzhynska M, et al. Establishing a hepatitis C continuum of care among HIV/HCV coinfected individuals in EuroSIDA. HIV Med. 2019.
Elvstam O, Medstrand P, Jansson M, et al. Is low-level HIV-1 viraemia associated with markers of immune activation and cardiovascular disease? HIV Med. 2019.
Elvstam O, Medstrand P, Yilmaz A, et al. Virological failure and mortality in HIV-positive adults with low-level viremia. PLoS One. 2017.
Hermansson L, Yilmaz A, Axelsson M, et al. CSF levels of the glial marker YKL-40 strongly associated with axonal injury in HIV infection. J Neuroinflammation. 2019.
Yilmaz A, Fuchs D, Price RW, et al. Cerebrospinal fluid concentrations of neurogranin in neuro-HIV. Curr HIV/AIDS Rep. 2019.
Hammarström H, Grankvist A, Broman I, et al. Serum-based diagnosis of Pneumocystis pneumonia by detection of DNA and 1,3-β-D-glucan. BMC Infect Dis. 2019.
Yilmaz A, Mellgren Å, Fuchs D, et al. Switching antiretroviral regimens does not affect CNS HIV-1 infection. Infect Dis. 2019.
Antiretroviral treatment for HIV infection: Swedish recommendations 2019. Infect Dis (Lond). 2020.
Mocroft A, Lundgren J, Gerstoft J, et al. Clinical outcomes in persons coinfected with HIV and hepatitis C: Impact of hepatitis C treatment. Clin Infect Dis. 2019.
Neesgaard B, Mocroft A, Zangerle R, et al. Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. PLoS One. 2020;15(12):e0243625.
Mellgren Å, Eriksson LE, Reinius M, et al. Longitudinal trends and determinants of patient-reported side effects on ART-a Swedish national registry study. PLoS One. 2020;15(12):e0242710.
Greenberg L, Ryom L, Neesgaard B, et al. Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV. Clin Infect Dis. 2020.
Ray S, Narayanan A, Giske CG, et al. Altered Gut Microbiome under Antiretroviral Therapy: Impact of Efavirenz and Zidovudine. ACS Infect Dis. 2020.
Lathouwers E, Weinsteiger S, Baugh B, et al. Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials. J Med Virol. 2020.
George-Svahn L, Eriksson L, Wiklander M, et al. Barriers to HIV testing as reported by individuals newly diagnosed with HIV infection in Sweden. 2020.
Carlander C, Lagheden C, Eklund C, et al. HPV Types in Cervical Precancer by HIV Status and Birth Region: A Population-Based Register Study. Cancer Epidemiol Biomarkers Prev. 2020;29(12):2662-2668.
Vourli G, Noori T, Pharris A, et al. HIV Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population. Clin Infect Dis. 2020;71(11):2905-2916.
The Respond Study Group. How to RESPOND to Modern Challenges for People Living with HIV: A Profile for a New Cohort Consortium. Microorganisms. 2020;8(8).
Hagberg L, Price RW, Zetterberg H, et al. Herpes zoster in HIV-1 infection: The role of CSF pleocytosis in secondary CSF escape and discordance. PLoS One. 2020;15(7):e0236162.
Schlösser M, Kartashev VV, Mikkola VH, et al. HIV-1 Sub-Subtype A6: Settings for Normalised Identification and Molecular Epidemiology in the Southern Federal District, Russia. Viruses. 2020;12(4).
CIPHER Global Cohort Collaboration. Outcomes of second-line antiretroviral therapy among children living with HIV: a global cohort analysis. J Int AIDS Soc. 2020;23(4):e25477.
Elvstam O, Marrone G, Medstrand P, et al. All-Cause Mortality and Serious Non-AIDS Events in Adults with Low-Level HIV Viremia during Combination Antiretroviral Therapy. Clin Infect Dis. 2020.
Boffito M, Ryom L, Spinner C, et al. Clinical management of ageing people living with HIV in Europe: the view of the care providers. Infection. 2020;48(4):497-506.
Lindqvist B, Svensson Akusjärvi S, et al. Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells. PLoS Pathog. 2020;16(1):e1008264.
Eriksen J, Carlander C, Albert J, et al. Antiretroviral treatment for HIV infection: Swedish recommendations 2019. Infect Dis (Lond). 2020;52(5):295-329.
Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1. J Virus Erad. 2020;6(1):19-26.
Andersson GZ, Reinius M, Eriksson LE, et al. Stigma reduction interventions in people living with HIV to improve health-related quality of life. Lancet HIV. 2020;7(2):e129-e140.
Carlander C, Lagheden C, Eklund C, et al. Nonvaccine human papillomavirus genotype common in women with HIV failing cervical precancer treatment. AIDS. 2021 Nov 15;35(14):2367-2374.
PubMed
Carlander C, Wagner P, Yilmaz A, et al. Employment by HIV status, mode of HIV transmission and migrant status: a nation-wide population-based study with twenty years of follow-up. AIDS. 2021 Jan 1;35(1):115-123.
PubMed
Carlsson-Lalloo E, Rusner M, Berg M, et al. People living with HIV in Sweden report high levels of sexual satisfaction in a registry-based cohort study. AIDS Care. 2021 Apr 1.
PubMed
Elvstam O, Marrone G, Medstrand P, et al. All-Cause Mortality and Serious Non-AIDS Events in Adults With Low-level HIV Viremia During Combination Antiretroviral Therapy. Clin Infect Dis. 2021 Jun 15;72(12):2079–2086.
PubMed
Elvstam O, Marrone G, Medstrand P, et al. Associations Between Plasma HIV RNA Levels and Incidence of Invasive Cancer in People With HIV After Initiation of Combination Antiretroviral Therapy. Open Forum Infect Dis. 2021 Jun.
PubMed
Kieri O, Marrone G, Sönnerborg A, et al. Incidence, treatment and outcome of HIV-associated hematologic malignancies in people living with HIV in Sweden. AIDS Res Hum Retroviruses. 2021.
PubMed
Malmström S, Wagner P, Yilmaz A, et al. Failure to restore CD4+ cell count associated with infection-related and noninfection-related cancer. AIDS. 2021 Online ahead of print Oct 27.
PubMed
Atkinson A, Zwahlen M, Barger D, et al. Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With HIV: An Emulation of a Pragmatic Trial in COHERE. Clin Infect Dis. 2021 Jul 15;73(2):195-202.
PubMed
Bansi-Matharu L, Phillips A, Oprea C, et al. Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium. Lancet HIV. 2021 Nov;8(11):e711-e722.
PubMed
Borghetti A, Ciccullo A, Lombardi F, et al. Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors. HIV Med. 2021 Jan;22(1):22-27.
PubMed
Caby F, Guiguet M, Weiss L, et al. CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated HIV Infection. Clin Infect Dis. 2021 Jul 1;73(1):50-59.
PubMed
The RESPOND Study Group. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. AIDS. 2021 May 1;35(6):869-992.
PubMed
Rossetti B, Fabbiani M, Domenico DC, et al. Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-experienced individuals: results from a European multicohort study. J Antimicrob Chemother. 2021 Aug 12;76(9):2394-2399.
PubMed
Use of InfCare HIV to identify and characterize suboptimally treated HIV patients at a Danish HIV clinic: a cross-sectional cohort study. Dalgaard LS, Søgaard OS, Jensen-Fangel S, Larsen CS, Sönnerborg A, Østergaard L.Scand J Infect Dis. 2012 Feb;44(2):108-14. doi: 10.3109/00365548.2011.616223. Epub 2011 Dec 27.PMID: 22200100
Kieri O, Marrone G, Sönnerborg A, Nowak P.Incidence, Treatment, and Outcome of HIV-Associated Hematologic Malignancies in People Living with HIV in Sweden.AIDS Res Hum Retroviruses. 2022 Feb;38(2):135-142. doi: 10.1089/AID.2021.0020. PMID: 34652958.
Sörstedt E, Tetens MM, Nilsson S, et al.Impact of pre-antiretroviral treatment HIV-RNA on time to successful virological suppression and subsequent virological failure.AIDS. 2023 Feb;37(2):279-286. doi: 10.1097/QAD.0000000000003425. PMID: 36541640.
Elvstam O, Marrone G, Engström G, et al.Associations between HIV viremia during antiretroviral therapy and cardiovascular disease.AIDS. 2022;36(13):1829-34.
Brattgård H, Björkman P, Nowak P, et al.Factors associated with low-level viraemia in people with HIV starting antiretroviral therapy: A Swedish observational study.PLOS ONE. 2022;17(5):e0268540.
Elvstam O, Malmborn K, Elén S, et al.Virologic failure following low-level viremia and viral blips during antiretroviral therapy.Clin Infect Dis. 2022 Sep 14:ciac762. doi: 10.1093/cid/ciac762. PMID: 36100984.
Malmström S, Wagner P, Yilmaz A, et al.Failure to restore CD4+ cell count associated with infection-related and noninfection-related cancer.AIDS. 2022 Mar;36(3):447-457. PMID: 34711738.
Carlsson-Lalloo E, Berg M, Rusner M, et al.Sexual satisfaction and its associations with patient-reported outcomes in women living with HIV in Sweden.Int J STD AIDS. 2022 Jul;33(8):751-760. doi: 10.1177/09564624221100056. PMID: 35622448.
Pirkl M, Arsalan N, Reuter B, et al.Analysis of mutational history of multi drug-resistant genotypes.J Med Virol. 2022 Dec 9. doi: 10.1002/jmv.28389. PMID: 36484375.
Jaschinski N, Greenberg L, Neesgard B, et al.Recent Abacavir Use and Incident Cardiovascular Disease in Contemporary Treated People Living with HIV.AIDS. 2022 Aug 24. doi: 10.1097/QAD.0000000000003373. PMID: 36001525.
Neesgaard B, Greenberg L, Miró J, et al.Association Between Integrase Strand Transfer Inhibitors and Cardiovascular Disease.Lancet HIV. 2022 Jul;9(7):e474-e485. doi: 10.1016/S2352-3018(22)00094-7. PMID: 35688166.
Greenberg L, Ryom L, Neesgaard B, et al.Integrase strand transfer inhibitor use and cancer incidence.Open Forum Infect Dis. 2022 Jan;9(3):ofac029. doi: 10.1093/ofid/ofac029. PMID: 35198646.
Rossetti B, Fabbiani MF, Di Carlo D, et al.Effectiveness of integrase strand transfer inhibitor in HIV-infected treatment-experienced individuals.HIV Med. 2022. doi: 10.1111/hiv.13273. PMID: 35233903.
Svensson-Akusjärvi S, Krishnan S, Jütte BB, et al.Peripheral blood CD4+CCR6+ compartment differentiates HIV-1 elite controllers.Commun Biol. 2022 Apr;5(1):357. doi: 10.1038/s42003-022-03315-x. PMID: 35418589.
Svensson Akusjärvi S, Ambikan AT, Krishnan S, et al.Integrative proteo-transcriptomic and immunophenotyping signatures of HIV-1 elite control phenotype.iScience. 2022 Jan;25(1):103607.
Tyrberg E, Hagberg L, Andersson LM, et al.The effect of vitamin B supplementation on neuronal injury in people living with HIV.Brain Commun. 2022 Oct;4(6):fcac259. doi: 10.1093/braincomms/fcac259. PMID: 36337345.
Hagberg L, Edén A, Zetterberg H, et al.Blood biomarkers for HIV infection with focus on neurologic complications.Acta Neurol Scand. 2022 Jul;146(1):56-60. doi: 10.1111/ane.13629. PMID: 35470863.
Xu X, Vesterbacka J, Aleman S, et al.High seroconversion rate after vaccination with mRNA BNT162b2 vaccine in people with HIV.AIDS. 2022 Mar;36(3):479-481. PMID: 35084386.
Carlander C, Brännström J, Månsson F, et al.Cohort profile: InfCareHIV, a prospective registry-based cohort study of people with diagnosed HIV in Sweden.BMJ Open. 2023 Mar 17;13(3):e069688. PMID: 36931676.
Hagberg L, Gisslén M.Cohort profile: a longitudinal study of HIV infection in the central nervous system with focus on cerebrospinal fluid - the Gothenburg HIV CSF Study Cohort.BMJ Open. 2023 May 17;13(5):e070693. PMID: 37197824.
Edén A, Rydberg F, Yilmaz A, et al.Residual Central Nervous System Immune Activation Is Not Prevented by Antiretroviral Therapy Initiated During Early Chronic HIV Infection.Open Forum Infect Dis. 2023 Feb;10(2):ofad064. PMID: 36861089.
Duran-Castells C, Llano A, Kawana-Tachikawa A, et al.Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction.J Virol. 2023 Feb 28;97(2):e0165522. PMID: 36719240.
Kincer LP, Joseph SB, Gilleece MM, et al.Rebound HIV-1 in cerebrospinal fluid after antiviral therapy interruption is mainly clonally amplified R5 T cell-tropic virus.Nat Microbiol. 2023 Feb;8(2):260-271. PMID: 36717718.
Ripamonti E, Edén A, Nilsson S, et al.Longitudinal decline of plasma neurofilament light levels after antiretroviral initiation in people living with HIV.J Intern Med. 2023 Apr;293(4):445-456. PMID: 36443917.
Reinius M, Svedhem V, Bruchfeld J, et al.COVID-19-related stigma among infected people in Sweden; psychometric properties and levels of stigma.PLoS One. 2023 Jun;18(6):e0287341. PMID: 37343027.
McKay KA, Wijnands JMA, Manouchehrinia A, et al.Risk of Multiple Sclerosis in People Living with HIV: An International Cohort Study.Ann Neurol. 2023 Dec; PMID: 38098141.
Mocroft A, Ryom L, Pelchen-Matthews A, et al.Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral Treated People with HIV.Clin Infect Dis. 2023 Dec; PMID: 38092042.
Greenberg L, Ryom L, Bakowska E, et al.Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV.Cancers (Basel). 2023 Jul;15(14):3640.
Mocroft A, Ryom L, Neesgaard B, et al.Plasma HIV-1 RNA and CD4+ T-cell count are determinants of virological non-suppression outcomes with initial integrase inhibitor-based regimens.Clin Infect Dis. 2023 Aug;77(4):593-605. PMID: 37052343.
Rossetti B, Incardona F, Mommo C, et al.Cohort profile: a European multidisciplinary network for the fight against HIV drug resistance (EuResist Network).Trop Med Infect Dis. 2023 Apr;8(5):243. PMID: 37235291.
Müller TR, Sekine T, Trubach D, et al.Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states.Sci Transl Med. 2023 Jul;15(704):eadg9452. PMID: 37437015.
Chen P, Bergman P, Blennow O, et al.Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination.EBioMedicine. 2023 Aug;94:104700. PMID: 37453361.
Vesterbacka J, Aleman S, Nowak P, et al.High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV.AIDS. 2023 Mar;36(3):479-481. PMID: 35084386.
